Zealand Pharma Reports Share Buy-Back Progress and PDMR Transactions Amid Metabolic Health Pipeline Push
核心洞察
Zealand Pharma executed share repurchases totaling DKK 54.1 million during week 23 of its ongoing buy-back program, bringing total accumulated repurchases to DKK 240.9 million.
The company now holds approximately 2.27% of its total share capital as treasury shares following the latest transactions and a concurrent capital increase.
Zealand Pharma disclosed transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons, maintaining regulatory transparency.
Zealand Pharma A/S (Nasdaq: ZEAL), the Copenhagen-based biotechnology company focused on metabolic health, has disclosed the latest transactions under its ongoing share buy-back program alongside separate notifications regarding dealings by managerial insiders, reinforcing the company's commitment to regulatory transparency as it advances its obesity-focused pipeline.
Share Buy-Back Program: Week 23 Transactions
During the trading period of June 1 through June 4, 2026, Zealand Pharma repurchased a total of 173,000 shares on Nasdaq Copenhagen (XCSE) at an aggregate transaction value of DKK 54,105,920. The daily breakdown shows consistent acquisition activity: 45,000 shares were purchased on each of June 1, 2, and 3 at average prices of DKK 316.96, DKK 309.90, and DKK 302.62 respectively, while 38,000 shares were acquired on June 4 at an average price of DKK 323.14.
These latest transactions bring the total accumulated repurchases under the program to 751,000 shares, representing a cumulative transaction value of DKK 240,880,840 since the program's commencement on May 7, 2026.
The buy-back program, originally announced on May 7, 2026, authorizes Zealand Pharma to repurchase shares for a total consideration of up to DKK 1.3 billion, with a maximum of 7,152,557 shares eligible for acquisition. The program is scheduled to conclude no later than October 31, 2026. Danske Bank (搜索) has been appointed as lead manager and makes trading decisions independently of the company, in accordance with the Safe Harbour Regulation under EU Market Abuse Regulation (MAR).
Treasury Holdings and Capital Structure
Following the week 23 transactions, Zealand Pharma holds a total of 1,621,482 treasury shares, corresponding to approximately 2.27% of the company's share capital. This figure incorporates a capital increase announced on June 8, 2026, whereby the company increased its share capital by a nominal amount of DKK 53,183, divided into 53,183 new shares, subject to final registration with the Danish Business Authority. The total number of shares in Zealand Pharma now amounts to 71,578,758, with each share carrying a nominal value of DKK 1.
PDMR Transaction Disclosures
In a separate regulatory filing dated June 10, 2026, Zealand Pharma published information regarding transactions in the company's shares or related securities conducted by persons discharging managerial responsibilities (PDMRs) and their closely associated persons. The company stated it had received notification of such transactions and published the details in accordance with MAR requirements. The specific nature and scale of these insider transactions were made available in the attached filing.
Company Profile and Pipeline Context
Zealand Pharma brings over 25 years of peptide research and development expertise to the metabolic health space. The company leverages a proprietary data platform incorporating advanced data-driven and AI/ML approaches to discover and develop novel medicines. To date, more than 10 Zealand-invented drug candidates have entered clinical development, with two products having reached the market and three candidates currently in late-stage development. The company maintains collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization activities. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts.